Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|TVB-2640||TVB2640||FASN Inhibitor 5||TVB-2640 is a fatty acid synthase (FASN) inhibitor that inhibits lipid metabolism in tumor cells (PMID: 26519059).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||TVB-2640||Phase I||Actionable||In a Phase I trial, TVB-2640 demonstrated bioavailability and inhibited FASN-dependent signaling in the tumor tissue of one patient with advanced solid tumor (Cancer Res August 1, 2015 75; 2675).||detail...|
|Unknown unknown||lung non-small cell carcinoma||not applicable||TVB-2640||Phase I||Actionable||In a Phase I study, TVB-2640 as a monotherapy or in combination with Taxol (paclitaxel) resulted in stable diseases for more than 16 weeks in 43% (3/7) of patients with non-small cell lung cancer (2015 51 S724-S724 Eur J Cancer).||detail...|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||TVB-2640||Phase I||Actionable||In a Phase I clinical trial, TVB-2640 treatment resulted in stable disease for 20 weeks in one patient with triple-receptor negative breast cancer (2015 51 S724-S724 Eur J Cancer).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02223247||Phase I||TVB-2640||A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors||Completed|
|NCT02980029||Phase I||TVB-2640||Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer||Recruiting|
|NCT03808558||Phase II||TVB-2640||Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas||Recruiting|